Current partner codePEPTIDESDE
NCT04561245·Phase 1·INTERVENTIONAL

ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

Status

Completed

Phase

Phase 1

Enrollment

100

Locations

1

Results

Not posted

Publications

0

Study summary

What the protocol is testing.

This study was a FIH, Phase 1, randomized, double-blind, placebo-controlled, 2-part single-ascending dose (SAD) and multiple-ascending dose (MAD) study of ALT-801 (pemvidutide) in healthy overweight and obese subjects. The purpose of the study was to assess the safety and tolerability in healthy overweight and obese volunteers administered single or multiple repeated doses of ALT-801 (pemvidutide).

Full detailed description

This study had 2 parts. Part 1 involved single dose cohorts of ALT-801 (pemvidutide) or placebo taken as a subcutaneous (SC) injection and was approximately 36 days in duration. Part 2 involved multiple dose cohorts of ALT-801 (pemvidutide) or placebo taken once a week for 12 weeks as a SC injection and was approximately 116 days in duration. Each participant enrolled in only one part.

Interventions

Treatment arms and agents.

DRUG

ALT-801

Injected subcutaneously (SC)

OTHER

Placebo

Injected subcutaneously (SC)

Timeline

From registration to results.

  1. First posted

    Sep 23, 2020

  2. Study start

    Nov 10, 2020

  3. Primary completion

    Oct 29, 2021

  4. Study completion

    Oct 29, 2021

  5. Results posted

    Not reported

  6. Registry updated

    Jun 24, 2025

Outcomes

What the study measures.

Primary outcomes

The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)

Time frame · Part 1 SAD Cohorts: up to Day 26; Part 2 MAD Cohorts: up to Day 42

Pharmacokinetic (PK): Maximum observed concentration (Cmax) of ALT-801

Time frame · Baseline, Day 26

Pharmacokinetic (PK): Area Under the Concentration (AUC) vs Time Curve of ALT-801

Time frame · Baseline to Day 26

Change in body weight

Time frame · Baseline to Week 6

Pharmacodynamic (PD): Change from baseline in magnetic resonance derived proton density fat fraction (MRI-PDFF)

Time frame · Baseline to Week 6

Secondary outcomes

Not reported in the indexed record.

Eligibility

Who can take part.

Minimum age
18 Years
Maximum age
60 Years
Sex
ALL
Healthy volunteers
Yes

Inclusion Criteria: * Male or female healthy volunteers, age 18 to 60 years, inclusive * Overweight to obese (BMI 25.0 - 40.0 kg/m2) * MRI-PDFF≥ 10% (Part 2 only) * Non-smokers or ex-smokers (must have ceased smoking \> 1 months prior to screening visit) * Subjects must otherwise be in good general health, with no significant medical history, have no clinically significant abnormalities on physical examination at screening, and/or before administration of the initial dose of study medication * Ability and willingness to attend the necessary visits to the study center * Written informed consent signed prior to entry into the study Exclusion Criteria: * Women who are pregnant or breastfeeding * History of pancreatitis * History of or acute significant GI disorder * History of diabetes or use of medications for the treatment of diabetes, or hyperglycemia or HbA1c ≥ 6.5% * History of clinically significant endocrine (eg, hypothyroidism), neurological, GI, cardiovascular (except controlled hypertension and hypercholesterolemia), hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases * History of neoplastic disease, or personal or family history of multiple endocrine neoplasia or medullary cancer of the thyroid, with the following exceptions: 1. Adequately treated non-melanomatous skin carcinoma 2. Female with a history of benign cervical neoplasia if the subject has been compliant with surveillance and treatment as recommended by her physician * Blood pressure \> 150/90 mmHg or heart rate \> 100 beats per minute at screening and at Day -1 * Clinically significant laboratory abnormalities including: Impaired renal function (estimated glomerular filtration rate \[eGFR\] \<60 mL/min/1.73m2) as estimated using the MDRD equation at screening: 1. GFR (mL/min/1.73 m²) = 175 × (SCr/88.4)-1.154 × (Age)-0.203 × (0.742 if female) × (1.212 if African American) (SI units), where SCr is standardized serum creatinine in SI units (µmol/L) and age is in years 2. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) laboratory values \> 2 × upper normal limits 3. Calcitonin \> 50 ng/L - Excessive alcohol consumption defined as \>21 alcohol units per week for males and as \>14 alcohol units per week for females (where 1 unit = half pint of beer, 25 mL of 40% spirit, or 125 mL of wine)

Study locations

1 registered sites.

Australia. Showing up to 24 locations stored in the fast local snapshot.

Nucleus Networks

Herston, Queensland, Australia

Publications

Results and literature.

No PMID-linked publications were present in this registry snapshot.

Primary links

Continue at the source.

Related trials

More studies on Pemvidutide.

Related PeptideStat pages

Put the record in context.

Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.